Fourthly, octreotide - a somatostatin analogue classically used to control hypersomatotropism in acromegaly through the inhibition of GH action and GH secretion [30] – has been reported to be an effective treatment for POTS patients by reducing upright tachycardia and symptoms of orthostatic intolerance due to its splanchnic vasoconstrictor effect [31]. This evidence concerns the gene GH1 and postural orthostatic tachycardia syndrome.